Search Result

Isoforms Recommended:	PARP2

Results for "

PARP-2

" in MedChemExpress (MCE) Product Catalog:

By Targets:	PARP (48) Apoptosis (12) Autophagy (5) Caspase (2) HDAC (1) Isotope-Labeled Compounds (2) Microtubule/Tubulin (2) Mitophagy (3) PI3K (1) PPAR (1) Small Interfering RNA (siRNA) (3)
By Research Areas:	Cancer (47) Neurological Disease (3)
Click Chemistry:	Alkynes (1)

Inhibitors & Agonists

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Click Chemistry

Targets Recommended: PARP

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-RS10060

PARP2 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)
PARP2 Human Pre-designed siRNA Set A contains three designed siRNAs for PARP2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

PARP2 Human Pre-designed siRNA Set A PARP2 Human Pre-designed siRNA Set A

HY-RS10061

Parp2 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)
Parp2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Parp2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Parp2 Mouse Pre-designed siRNA Set A Parp2 Mouse Pre-designed siRNA Set A

HY-RS10062

Parp2 Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)
Parp2 Rat Pre-designed siRNA Set A contains three designed siRNAs for Parp2 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Parp2 Rat Pre-designed siRNA Set A Parp2 Rat Pre-designed siRNA Set A

HY-102035

PARP-2-IN-1

PARP Cancer

PARP-2-IN-1 is a potent and selective PARP-2 inhibitor with an IC₅₀ of 11.5 nM.

PARP-2-IN-1	PARP	Cancer
PARP-2-IN-1 is a potent and selective *PARP-2* inhibitor with an IC₅₀ of 11.5 nM.

HY-151625

PARP-2-IN-3	PARP Apoptosis	Cancer
PARP-2-IN-3 (Compound 12) is a potent *PARP-2* inhibitor with an IC₅₀ of 0.07 μM. PARP-2-IN-3 induces apoptosis and necrosis in cancer cells. PARP-2-IN-3 shows appropriate predicted pharmacokinetic parameters and oral bioavailability .

HY-151624

PARP-2-IN-2	PARP Apoptosis	Cancer
PARP-2-IN-2 (compound 27) is a *PARP‑2* inhibitor with an IC₅₀ value of 0.057 µM. PARP-2-IN-2 induces cell cycle arrest and apoptosis of MCF-7 breast cancer cells. PARP-2-IN-2 can be used for the research of cancer .

HY-105253

PARP-2/1-IN-2	PARP	Neurological Disease
PARP-2/1-IN-2 (Compound 4a), the enantiomer of Veliparib (HY-10129), is a potent *PARP* inhibitor with K_is of 2 and 5 nM against *PARP-2* and *PARP-1, respectively. PARP-2/1-IN-2 has an EC₅₀ of 3 nM in a cell based assay of PARP* activity .

HY-105303

CEP-9722	PARP	Cancer
CEP-9722, the proagent of CEP-8983, is a selective and orally active *PARP-1* and *PARP-2* inhibitor with IC₅₀s of 20 nM and 6 nM, respectively. CEP-9722 has anticancer effects ^[2].

HY-10617D

Rucaparib acetate AG014699 acetate; PF-01367338 acetate	PARP	Cancer
Rucaparib (AG014699) acetate is an orally active, potent inhibitor of *PARP* proteins (PARP-1, PARP-2 and PARP-3) with a K_i of 1.4 nM for PARP1. Rucaparib acetate is a modest hexose-6-phosphate dehydrogenase (H6PD) inhibitor. Rucaparib acetate has the potential for castration-resistant prostate cancer (CRPC) research ^[2] .

HY-10617B

Rucaparib hydrochloride AG014699 hydrochloride; PF-01367338 hydrochloride	PARP	Cancer
Rucaparib (AG014699) hydrochloride is an orally active, potent inhibitor of *PARP* proteins (PARP-1, PARP-2 and PARP-3) with a K_i of 1.4 nM for PARP1. Rucaparib hydrochloride is a modest hexose-6-phosphate dehydrogenase (H6PD) inhibitor. Rucaparib hydrochloride has the potential for castration-resistant prostate cancer (CRPC) research ^[2] .

HY-10617C

Rucaparib tartrate AG-014699 tartrate; PF-01367338 tartrate	PARP	Cancer
Rucaparib (AG014699) tartrate is an orally active, potent inhibitor of *PARP* proteins (PARP-1, PARP-2 and PARP-3) with a K_i of 1.4 nM for PARP1. Rucaparib tartrate is a modest hexose-6-phosphate dehydrogenase (H6PD) inhibitor. Rucaparib tartrate has the potential for castration-resistant prostate cancer (CRPC) research ^[2] .

HY-14478

UPF 1069

1 Publications Verification

PARP Cancer

UPF 1069 is a PARP inhibitor, with IC₅₀s of 8 and 0.3 μM for PARP-1 and PARP-2, respectively.

UPF 1069 1 Publications Verification	PARP	Cancer
UPF 1069 is a *PARP* inhibitor, with IC₅₀s of 8 and 0.3 μM for PARP-1 and PARP-2, respectively.

HY-12418

Stenoparib 1 Publications Verification E7449; 2X-121	PARP	Cancer
Stenoparib (E7449) is a potent *PARP1* and *PARP2* inhibitor and also inhibits TNKS1 and *TNKS2, with IC₅₀s of 2.0, 1.0, ∼50 and ∼50 nM for PARP1, PARP2*, TNKS1 and TNKS2, respectively, using ³²P-NAD ⁺ as substrate.

HY-148754

PARP10-IN-3	PARP	Cancer
PARP10-IN-3 is a selective mono‐ADP‐ribosyltransferase *PARP10* inhibitor with an IC₅₀ of 480 nM for human PARP10. PARP10-IN-3 reveals potent inhibition on *PARP2* and *PARP15* with IC₅₀s of 1.7 μM for human PARP2 and human PARP15, respectively .

HY-146336

PARP1/2/TNKS1/2-IN-1	PARP Apoptosis	Cancer
PARP1/2/TNKS1/2-IN-1 (Compound I-9) is a dual *PARP-1, PARP-2, TNKS1* and *TNKS2* inhibitor with IC₅₀ values of 0.25 nM, 1.2 nM, 13.5 nM and 4.15 nM against PARP-1, PARP-2, TNKS1 and TNKS2, respectively. PARP1/2/TNKS1/2-IN-1 exhibits favorable synergistic antitumor efficacy and induces apoptosis .

HY-148753

PARP10-IN-2	PARP	Cancer
PARP10-IN-2 is a potent mono‐ADP‐ribosyltransferase *PARP10* inhibitor with an IC₅₀ of 3.64 μM for human PARP10. PARP10-IN-2 reveals potent inhibition on *PARP2* and *PARP15* with IC₅₀s of 27 μM and 11 μM for human PARP2 and human PARP15, respectively .

HY-10129

Veliparib

25+ Cited Publications

ABT-888
PARP Autophagy Cancer

Veliparib (ABT-888) is a potent PARP inhibitor, inhibiting PARP1 and PARP2 with K_is of 5.2 and 2.9 nM, respectively .
HY-13536

AZD-2461

5+ Cited Publications

PARP Cancer

AZD-2461 is a potent PARP inhibitor, with IC₅₀s of 5 nM, 2 nM and 200 nM for PARP1, PARP2 and PARP3, respectively.
HY-10614

A-966492

3 Publications Verification

PARP Cancer

A-966492 is a novel and potent inhibitor of PARP1 and PARP2 with K_i of 1 nM and 1.5 nM, respectively.

Veliparib 25+ Cited Publications ABT-888	PARP Autophagy	Cancer
Veliparib (ABT-888) is a potent *PARP* inhibitor, inhibiting *PARP1* and *PARP2* with K_is of 5.2 and 2.9 nM, respectively .

AZD-2461 5+ Cited Publications	PARP	Cancer
AZD-2461 is a potent *PARP* inhibitor, with IC₅₀s of 5 nM, 2 nM and 200 nM for PARP1, PARP2 and PARP3, respectively.

A-966492 3 Publications Verification	PARP	Cancer
A-966492 is a novel and potent inhibitor of PARP1 and PARP2 with K_i of 1 nM and 1.5 nM, respectively.

HY-157137

PARP1-IN-17	PARP Caspase Apoptosis	Cancer
PARP1-IN-17 is a *PARP-1* inhibitor (IC₅₀ = 19.24 nM for *PARP-1* and = 32.58 nM for PARP-2) and induce apoptosis. PARP1-IN-17 shows excellent anti-proliferative activity .

HY-10130

Veliparib dihydrochloride 25+ Cited Publications ABT-888 dihydrochloride	PARP Autophagy	Cancer
Veliparib (dihydrochloride) is a potent inhibitor of PARP1* and PARP2 with K_is of* 5.2 nM and 2.9 nM in cell-free assays, respectively.

HY-14688

CEP-8983	PARP	Cancer
CEP-8983 is a *PARP-1* and *PARP-2* inhibitor (IC₅₀: 20 and 6 nM). CEP-8983 is an effective chemosensitizing agent, and can sensitize chemotherapy-resistant cell lines and subcutaneous xenografts to Temozolomide (HY-17364) and Camptothecin (HY-16560) .

HY-13990

NVP-TNKS656 TNKS656	PARP Apoptosis	Cancer
NVP-TNKS656 is a highly potent, selective, and orally active *TNKS2* inhibitor with IC₅₀ of 6 nM, and is > 300 fold selectivity against *PARP1* and *PARP2*.

HY-119653

AZ9482

PARP Cancer

AZ9482 is a triple PARP1/2/6 inhibitor, with IC₅₀ values of 1 nM, 1 nM and 640 nM for PARP1, PARP2 and PARP6, respectively .

AZ9482	PARP	Cancer
AZ9482 is a triple *PARP1/2/6* inhibitor, with IC₅₀ values of 1 nM, 1 nM and 640 nM for PARP1, PARP2 and PARP6, respectively .

HY-105692

DR2313	PARP	Neurological Disease
DR2313 is a potent, selective, competitive and brain-penetrant inhibitor of poly(ADP-ribose) polymerase (PARP), with IC₅₀s of 0.20 μM and 0.24 μM for *PARP-1* and *PARP-2*, respectively. DR2313 exhibits neuroprotective effects on ischemic injuries in vitro and in vivo ^[2].

HY-10162

Olaparib Maximum Cited Publications 183 Publications Verification AZD2281; KU0059436	PARP Autophagy Mitophagy	Cancer
Olaparib (AZD2281; KU0059436) is a potent and orally active *PARP* inhibitor with IC₅₀s of 5 and 1 nM for *PARP1* and *PARP2, respectively. Olaparib is an autophagy* and mitophagy activator ^[2] .

HY-10617

Rucaparib phosphate 30+ Cited Publications AG-014699 phosphate; PF-01367338 phosphate	PARP	Cancer
Rucaparib (AG014699) phosphate is an orally active, potent inhibitor of *PARP* proteins (PARP-1, PARP-2 and PARP-3) with a K_i of 1.4 nM for PARP1. Rucaparib phosphate is a modest hexose-6-phosphate dehydrogenase (H6PD) inhibitor. Rucaparib phosphate has the potential for castration-resistant prostate cancer (CRPC) research ^[2] .

HY-10617A

Rucaparib 30+ Cited Publications AG014699; PF-01367338	PARP	Cancer
Rucaparib (AG014699) is an orally active, potent inhibitor of *PARP* proteins (PARP-1, PARP-2 and PARP-3) with a K_i of 1.4 nM for PARP1. Rucaparib is a modest hexose-6-phosphate dehydrogenase (H6PD) inhibitor. Rucaparib has the potential for castration-resistant prostate cancer (CRPC) research ^[2] .

HY-102003

Rucaparib monocamsylate 2 Publications Verification AG014699 monocamsylate; PF-01367338 monocamsylate	PARP	Cancer
Rucaparib (AG014699) monocamsylate is an orally active, potent inhibitor of *PARP* proteins (PARP-1, PARP-2 and PARP-3) with a K_i of 1.4 nM for PARP1. Rucaparib monocamsylate is a modest hexose-6-phosphate dehydrogenase (H6PD) inhibitor. Rucaparib monocamsylate has the potential for castration-resistant prostate cancer (CRPC) research ^[2] .

HY-102003A

Rucaparib camsylate AG014699 camsylate; PF-01367338 camsylate	PARP	Cancer
Rucaparib (AG014699) camsylate is an orally active, potent inhibitor of *PARP* proteins (PARP-1, PARP-2 and PARP-3) with a K_i of 1.4 nM for PARP1. Rucaparib camsylate is a modest hexose-6-phosphate dehydrogenase (H6PD) inhibitor. Rucaparib camsylate has the potential for castration-resistant prostate cancer (CRPC) research ^[2] .

HY-143338

ART-IN-1

PARP Cancer

ART-IN-1 (compound 7) is a selective PARP inhibitor with IC₅₀s of 19, 22, 2.4, >100, 1.1 µM for PARP2, TNKS2, PARP10, PARP14, PARP15, respectively .
HY-W294889

OUL245

PARP Cancer

OUL245 is a 7-Hydroxy derivative, and a selectively PARP2 inhibitor (IC₅₀=44 nM). OUL245 also inhibits other PARP and TNKS enzymes with IC₅₀s of 2.9-8.8 μM .

ART-IN-1	PARP	Cancer
ART-IN-1 (compound 7) is a selective *PARP* inhibitor with IC₅₀s of 19, 22, 2.4, >100, 1.1 µM for PARP2, TNKS2, PARP10, PARP14, PARP15, respectively .

OUL245	PARP	Cancer
OUL245 is a 7-Hydroxy derivative, and a selectively *PARP2* inhibitor (IC₅₀=44 nM). OUL245 also inhibits other PARP and TNKS enzymes with IC₅₀s of 2.9-8.8 μM .

HY-108632

BYK204165	PARP	Cancer
BYK204165 is a potent and selective *PARP1* inhibitor. BYK204165 inhibits cell-free recombinant human PARP-1 (hPARP-1) with a pIC₅₀ of 7.35 (pK_i=7.05), and murine PARP-2 (mPARP-2) with a pIC₅₀ of 5.38, respectively. BYK204165 displays 100-fold selectivity for PARP-1 .

HY-149800

PARP-1-IN-3	PARP Apoptosis Caspase	Cancer
PARP-1-IN-3, a benzamide derivative, is a potent *PARP-1* inhibitor with IC₅₀ values of 0.25 nM and 2.34 nM for PARP-1 and PARP-2, respectively. PARP-1-IN-3 induces apoptosis and arrest cell cycle at G2/M phase. PARP-1-IN-3 can be used in research of cancer .

HY-16106

Talazoparib 60+ Cited Publications BMN-673; LT-673	PARP	Cancer
Talazoparib (BMN-673) is a highly potent, orally active *PARP1/2* inhibitor.Talazoparib inhibits PARP1 and PARP2 enzyme activity with K_is of 1.2 nM and 0.87 nM, respectively. Talazoparib has antitumor activity .

HY-132167

Saruparib 3 Publications Verification AZD5305	PARP	Cancer
Saruparib (AZD5305) is a potent, orally active and selective *PARP* inhibitor and trapper with IC₅₀ values of 3 nM and 1400 nM for PARP1 and PARP2, respectively. Saruparib has anti-proliferative activity and inhibits growth in cells with deficiencies in DNA repair ^[2].

HY-157490

PARP/HDAC-IN-1	PARP HDAC	Cancer
PARP/HDAC-IN-1 (compound B102) is a potent dual inhibitor of *PARP* and HDAC. PARP/HDAC-IN-1 inhibits *PARP1, PARP2* and HDAC1 with IC₅₀s of 19.01, 2.13, 1690 nM, respectively .

HY-10619B

Niraparib tosylate 50+ Cited Publications MK-4827 tosylate	PARP Apoptosis	Cancer
Niraparib tosylate (MK-4827 tosylate) is a highly potent and orally bioavailable *PARP1* and *PARP2* inhibitor with an IC₅₀ of 3.8 and 2.1 nM, respectively. Niraparib tosylate leads to inhibition of repair of DNA damage, activates apoptosis and shows anti-tumor activity ^[2] .

HY-10162S1

Olaparib-d8 AZD2281-d₈; KU0059436-d₈	PARP Autophagy Mitophagy	Cancer
Olaparib-d₈ is the deuterium labeled Olaparib (AZD2281). Olaparib is a potent and orally active PARP inhibitor with IC50s of 5 and 1 nM for PARP1 and PARP2, respectively. Olaparib is an autophagy and mitophagy activator[1][2][3][4].

HY-147886

PARP1-IN-11	PARP	Cancer
PARP1-IN-11 (compound 49) is a potent *PARP1* inhibitor with IC₅₀ value of 0.082 µM. PARP1-IN-11 shows complete inhibition of PARP2 and substantially inhibits PARP3, TNKS1 and TNKS2 .

HY-10619

Niraparib 50+ Cited Publications MK-4827	PARP Apoptosis	Cancer
Niraparib (MK-4827) is a highly potent and orally bioavailable *PARP1* and *PARP2* inhibitor with IC₅₀s of 3.8 and 2.1 nM, respectively. Niraparib leads to inhibition of repair of DNA damage, activates apoptosis and shows anti-tumor activity ^[2] .

HY-10619A

Niraparib hydrochloride 50+ Cited Publications MK-4827 hydrochloride	PARP Apoptosis	Cancer
Niraparib hydrochloride (MK-4827 hydrochloride) is a highly potent and orally bioavailable *PARP1* and *PARP2* inhibitor with IC₅₀s of 3.8 and 2.1 nM, respectively. Niraparib hydrochloride leads to inhibition of repair of DNA damage, activates apoptosis and shows anti-tumor activity ^[2] .

HY-10619E

Niraparib tosylate hydrate 50+ Cited Publications MK-4827 tosylate hydrate	PARP Apoptosis	Cancer
Niraparib (MK-4827) tosylate hydrate is a highly potent and orally bioavailable *PARP1* and *PARP2* inhibitor with IC₅₀s of 3.8 and 2.1 nM, respectively. Niraparib tosylate hydrate leads to inhibition of repair of DNA damage, activates apoptosis and shows anti-tumor activity ^[2] .

HY-10162S3

Olaparib-d4-1 AZD2281-d₄-1; KU0059436-d₄-1	Isotope-Labeled Compounds PARP Autophagy Mitophagy	Cancer
Olaparib-d₄-1 is the deuterium labeled Olaparib. Olaparib (AZD2281; KU0059436) is a potent and orally active PARP inhibitor with IC50s of 5 and 1 nM for PARP1 and PARP2, respectively. Olaparib is an autophagy and mitophagy activator[1][2][3][4].

HY-16106S

Talazoparib-13C,d4 BMN-673-¹³C,d₄; LT-673-¹³C,d₄	Isotope-Labeled Compounds	Others
Talazoparib- ¹³C,d4 is ¹³C and deuterated labeled Talazoparib (HY-16106). Talazoparib is an orally active PARP 1/2 inhibitor with Ki values of 1.2 nM and 0.87 nM for inhibiting PARP1 and PARP2 enzymatic activities, respectively. Has anti-tumor activity.

HY-104044

Pamiparib 2 Publications Verification BGB-290	PARP	Cancer
Pamiparib (BGB-290) is an orally active, potent, highly selective *PARP* inhibitor, with IC₅₀ values of 0.9 nM and 0.5 nM for *PARP1* and *PARP2, respectively. Pamiparib has potent PARP* trapping, and capability to penetrate the brain, and can be used for the research of various cancers including the solid tumor ^[2].

HY-137457

Venadaparib IDX-1197	PARP	Cancer
Venadaparib (IDX-1197) is a potent, selective and orally active *PARP* inhibitor with IC₅₀s of 1.4 nM and 1.0 nM for *PARP1* and *PARP2, respectively. Venadaparib does not sensitive to PARP*-5. Venadaparib prevents the repair of DNA single-strand breaks (SSB) and can be used for solid tumors research ^[2].

HY-12975

AZ6102 1 Publications Verification	PARP	Cancer
AZ6102 is a potent dual TNKS1 and *TNKS2* inhibitor, with IC₅₀s of 3 nM and 1 nM, respectively, and alao has 100-fold selectivity against other PARP family enzymes, with IC₅₀s of 2.0 μM, 0.5 μM, and >3 μM, for PARP1, PARP2, and PARP6, respectively.

HY-145804

AZD-9574 1 Publications Verification	PPAR	Neurological Disease
AZD-9574 is a potent and brain penetrant *PARP1* inhibitor and shows >8000-fold selectivity for PARP1 compared to PARP2/3/5a/6. AZD-9574 acts by selectively inhibiting and trapping PARP1 at the sites of SSBs. AZD-9574 is an anti-cancer agent and can be used for HRD ⁺ breast cancer and advanced solid malignancies research .

HY-157320

*Tubulin/PARP-IN-2*	Microtubule/Tubulin Apoptosis	Cancer
Tubulin/PARP-IN-2 (compound 14) is a dual *PARP-Tubulin* inhibitor. Tubulin/PARP-IN-2 inhibits PARP1, PARP2, and tubulin activity with IC₅₀ values of 74 nM, 109 nM, and 1.4 µM, respectively. Tubulin/PARP-IN-2 induces apoptosis as well as autophagy. Tubulin/PARP-IN-2 causes cell cycle arrest at the G2/M phase .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote